sideBackce-47_158x176Microscience was founded and seeded by Sir Chris in 1996 to facilitate the exploitation of a unique signature tagged mutagenesis platform technology and vaccine development programme built at Imperial College.  The core technologies included a propriety oral delivery technology called spi-VECTM, which is still in use today and enables self administered drinkable vaccines.

Over the course of three funding rounds, Sir Chris was instrumental in developing the company over the course of three funding rounds raising $60m from new investors including Apax, Advent and JP Morgan.  The vaccine products went on to develop into a broad portfolio that included five clinical stage vaccines including an oral vaccine programme against the bioterror threat of Anthrax.

As a testament to the quality of the science, the company was also  recipient to the largest ever single Wellcome Trust Strategic Translation Award of $3 million in 2005.

Ultimately the business was sold to Emergent Biosolutions who went on to IPO the entire group for $280m on NYSE.  By that time, Microscience had developed a very impressive and broad intellectual property estate including 18 patent families covering 350 genes with 101 initial applications established.

bacteria.94120838_std_96x76  m0560093_92x77  18-micro-bact_100x70  18-micro-m_ningo-micro_science_110x73